• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 2
  3. Authors

Online ISSN: 2515-8260

Volume8, Issue2

Assessment Of Erythropoietin Efficacy And Dosing In Hemodialysis Patients

    Mostafa Fawzy Mohamed Selim Essam Eldin Mahmoud Lotfy Lamiaa Abd Elwahab Mohamed Mahmoud Hosny Zahran

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 2, Pages 2461-2469

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Anemia is a common complication in Chronic kidney disease (CKD) patients. It has a multi-factorial pathogenesis. Replenishing iron stores and giving ESAs are the main lines of treatment. There is a general agreement on the optimal route for iron supplementation in ESRD patients with the IV route but there is no such agreement on the optimal route for iron supplementation in pre-dialysis CKD patients. Erythropoiesis stimulating agents (ESAs) treatment represent an economic burden and has been linked to possible cardiovascular side effects. This study amid to assessing the efficacy of erythropoietin in treatment of anemia in CKD patients. Methods: A prospective cohort study was conducted in chronic kidney disease patients who had undergone hemodialysis in Met-Ghamr hospital of nephrology from February 2019 to July 2019. Included 50 patients on maintenance hemodialysis, we tested the efficacy through comparing the efficacy low fixed ESA dose (4000 IU IV once weekly) versus high fixed dose (4000 IU IV three times weekly). We divided group into two groups, group A and group B. group A were put on a fixed dose of 4000 IU Epoetin alfa once weekly and group B were put on a fixed dose of 4000 IU Epoetin alfa three times weekly. Results: After 6 months, We found a significant difference in hemoglobin response of the two subgroups in favor of subgroup IID (P = 0.004). Conclusion: That low dose ESAs is less effective in correction of anemia in dialysis patients than high dose ESAs.
Keywords:
    Erythropoietin stimulating agents chronic kidney disease Glomerular filtration rate Anemia iron
  • PDF (279 K)
  • XML
(2021). Assessment Of Erythropoietin Efficacy And Dosing In Hemodialysis Patients. European Journal of Molecular & Clinical Medicine, 8(2), 2461-2469.
Mostafa Fawzy Mohamed Selim; Essam Eldin Mahmoud Lotfy; Lamiaa Abd Elwahab Mohamed; Mahmoud Hosny Zahran. "Assessment Of Erythropoietin Efficacy And Dosing In Hemodialysis Patients". European Journal of Molecular & Clinical Medicine, 8, 2, 2021, 2461-2469.
(2021). 'Assessment Of Erythropoietin Efficacy And Dosing In Hemodialysis Patients', European Journal of Molecular & Clinical Medicine, 8(2), pp. 2461-2469.
Assessment Of Erythropoietin Efficacy And Dosing In Hemodialysis Patients. European Journal of Molecular & Clinical Medicine, 2021; 8(2): 2461-2469.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 335
  • PDF Download: 524
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus